Keros Therapeutics Posts $14.2 Million Q3 Profit
The biotech swung from a prior-year loss, driven by revenue tied to its Takeda license agreement.
Updated on Nov. 5, 2026 in Corporate Finance
Keros Therapeutics reported net income of $14.2 million for the third quarter of 2026, compared with a net loss of $7.3 million in the same quarter of 2025. The increase was primarily due to revenue recognized in 2026 from the company's license agreement with Takeda.
Why it matters
The result shows a shift from a loss-making quarter to profitability for the Lexington-based company, and it reflects the financial effect of its partnership with Takeda. Keros also reported $259.5 million in cash and equivalents, which it says will fund operations into the second half of 2028.
Research and development expenses were $20.5 million and general and administrative expenses were $6.7 million in the quarter, with G&A down $3.4 million year over year. Basic net income per share was $0.71 on 19,886,097 weighted-average shares.
The players
Keros Therapeutics
A clinical-stage biopharmaceutical company headquartered in Lexington, Massachusetts, developing therapies for muscle and bone-related diseases.
Takeda
A global pharmaceutical company that holds a license agreement with Keros and took over elritercept-related activities in 2025.
The details
Keros recognized revenue in 2026 under its license agreement with Takeda, which drove the quarter's profit. Research and development spending rose $1.0 million as the company advanced its pipeline, partly offset by lower elritercept-related costs after those activities transitioned to Takeda in 2025. In September 2026, Keros dosed the first patient in its Phase 2 rinvatercept trial for Duchenne muscular dystrophy, and it nominated KER-206 from its nonclinical pipeline.
Timeline
September 2026: First patient dosed in the Phase 2 rinvatercept trial for Duchenne muscular dystrophy.
September 30, 2026: Quarter ended with $259.5 million in cash and cash equivalents.
October 2026: Nonclinical RKER-206 poster presented at the ASBMR 2026 Annual Meeting.
First half of 2027: Keros expects to announce initial rinvatercept Phase 2 data.
Market Landscape
Keros' swing to profitability depends on its license agreement with Takeda rather than on product sales, which is typical for clinical-stage biotechs that partner early. The quarter's results reflect a financing model in which a larger drug developer shares development costs and recognizes revenue from the collaboration.
For investors, the quarter shows a return to positive net income driven by a one-time-style licensing recognition, which may not repeat in later periods. Shareholders will want to watch the rinvatercept data expected in 2027, since the company's cash runway extends only into the second half of 2028.
The takeaway
Keros' profit this quarter came from a partnership payment rather than from selling a drug, so investors should weigh the company's pipeline progress and cash runway when judging its longer-term outlook.
What happens next
Keros expects to announce initial data from its Phase 2 rinvatercept trial in the first half of 2027.
Further reading
For more on how Massachusetts drugmakers report their earnings, see Corporate Finance.
Source note: This article includes information reported by The Manila times.
